# HCM catalysts: HUTCHMED (China) Ltd PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/hcm/catalysts

> HUTCHMED (China) Ltd (HCM) has 12 upcoming catalysts. The next is the HMPL-760 topline data readout, Apr to Jul 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | HUTCHMED (China) Ltd |
| Ticker | HCM (Nasdaq) |
| SEC CIK | 1648257 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/hcm |

## Cash runway

Cash $1.37B as of 2025-12-31; quarterly burn $16.2M; about 253.6 months of runway at that rate (XBRL company facts, accession 0001104659-26-023822).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jan 2022 | [HMPL-653 trial start](https://sec-api.dev/pdufa/hmpl-653) | HCM | advanced or metastatic solid tumors and TGCT | completed | "In January 2022, we started China Phase I open-label, single-arm study of HMPL-653 in patients with advanced or metastatic solid tumors and TGCT." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1648257/000141057825000377/hcm-20241231x20f.htm)) |
| Apr 2022 | [SULANDA® (surufatinib) complete response letter (CRL)](https://sec-api.dev/pdufa/surufatinib) | HCM | pNETs and non-pancreatic NETs | completed, complete response letter | "In April 2022, we received a Complete Response Letter from the FDA regarding the NDA for surufatinib for the treatment of pNETs and non-pancreatic NETs." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1648257/000141057825000377/hcm-20241231x20f.htm)) |
| Jul 2022 | [TAZVERIK® (tazemetostat) trial start](https://sec-api.dev/pdufa/tazemetostat) | HCM |  | completed | "In July 2022, we initiated a China Phase II open-label, two-cohort bridging study of tazemetostat in r/r ≥3L FL intended to support conditional registration in China." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1648257/000141057825000377/hcm-20241231x20f.htm)) |
| Aug 2022 | [HUTCHMED (China) Ltd interim data readout](https://sec-api.dev/companies/hcm/catalysts) | HCM |  | completed, positive | "In August 2022, positive interim results from the SAVANNAH trial were presented at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer (WCLC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000164825725000022/hcm-20250320xex99d1.htm)) |
| Jul 2023 | [HMPL-415 trial start](https://sec-api.dev/pdufa/hmpl-415) | HCM | advanced malignant solid tumors | completed | "In July 2023, we initiated a China Phase I open-label study of HMPL-415 as a single agent in patients with advanced malignant solid tumors." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1648257/000110465926023822/hcm-20251231x20f.htm)) |
| Mar 2024 | [Sovleplenib trial start](https://sec-api.dev/pdufa/sovleplenib) | HCM | wAIHA in China | completed | "In March 2024, we initiated the Phase III registration part of the Phase II/III clinical trial of sovleplenib in adult patients with wAIHA in China." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1648257/000110465926023822/hcm-20251231x20f.htm)) |
| Jun 2024 | [HMPL-506 trial start](https://sec-api.dev/pdufa/hmpl-506) | HCM | hematological malignancies | completed | "In June 2024, we initiated China Phase I open-label study of HMPL-506 in patients with hematological malignancies." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1648257/000110465926023822/hcm-20251231x20f.htm)) |
| Nov 2024 | [HMPL-760 trial start](https://sec-api.dev/pdufa/hmpl-760) | HCM | r/r DLBCL | completed | "In November 2024, we started China Phase II randomized, active-controlled study of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with r/r DLBCL." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1648257/000110465926023822/hcm-20251231x20f.htm)) |
| Jan 2025 | [Olevaprubart topline data readout](https://sec-api.dev/pdufa/olevaprubart) | HCM |  | completed, positive | "A Phase IIa for the same trial (NCT05984784) reported positive topline data from patients in the U.S. and Canada in January 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1648257/000110465926023822/hcm-20251231x20f.htm)) |
| Q1 2025 | [Olevaprubart trial start](https://sec-api.dev/pdufa/olevaprubart) | HCM | moderate-to-severe atopic dermatitis | scheduled | "Initiation of a Phase IIb dose-finding study with IMG-007's subcutaneous formulation in patients with moderate-to-severe atopic dermatitis is planned for the first quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000110465925025364/tm2423664d2_ex99-1.htm)) |
| Jan 2025 | [Inmagene topline data readout](https://sec-api.dev/pdufa/inmagene) | HCM |  | completed, positive | "Inmagene reported positive topline data from patients in the US and Canada in January 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000110465925025364/tm2423664d2_ex99-1.htm)) |
| Mar 2025 | [TQB3702 trial start](https://sec-api.dev/pdufa/tqb3702) | HCM |  | scheduled | "TQB3702 is in Phase II study for B-cell lymphoma since November 2024 and plans to start a Phase II study in SLE in March 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1648257/000141057825000377/hcm-20241231x20f.htm)) |
| Mar 2025 | [Dabogratinib trial start](https://sec-api.dev/pdufa/dabogratinib) | HCM |  | scheduled | "TYRA300 plans to start a Phase II study for achondroplasia with open growth plates in March 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1648257/000141057825000377/hcm-20241231x20f.htm)) |
| Apr 2025 | [Tacabrutideg trial start](https://sec-api.dev/pdufa/tacabrutideg) | HCM |  | scheduled | "BGB-16673, a BTK degrader, plans to start a Phase III study for 3L CLL post-BTK and BCL2 in April 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1648257/000141057825000377/hcm-20241231x20f.htm)) |
| May 2025 | [Bleximenib trial start](https://sec-api.dev/pdufa/bleximenib) | HCM |  | scheduled | "Bleximenib (JNJ6617) plans to start a Phase III study for 1L AML with KMT2A rearrangement or NPM1 mutation in May 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1648257/000141057825000377/hcm-20241231x20f.htm)) |
| May 16, 2025 | [Sovleplenib primary completion](https://sec-api.dev/pdufa/sovleplenib) | HCM | Primary Immune Thrombocytopenia (ITP) | completed | "NCT05029635 (Phase III Study on HMPL-523 for Treatment of ITP): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-16 (ACTUAL); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05029635)) |
| Jul 2025 | [Olevaprubart trial start](https://sec-api.dev/pdufa/olevaprubart) | HCM |  | completed | "Dosed the first patient in a US Phase IIb randomized, double-blind, placebo-controlled dose-finding study of IMG-007 for moderate-to-severe atopic dermatitis in July 2025, targeting to enroll 220 patients who have had inadequate response to and/or intolerance of topical therapies (NCT07037901)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000141057825001583/hcm-20250807xex99d1.htm)) |
| 2H 2025 | [AiRuiKa® (camrelizumab) topline data readout](https://sec-api.dev/pdufa/camrelizumab) | HCM |  | scheduled | "Phase II/III trial on SULANDA® (surufatinib) in combination with AiRuiKa® (camrelizumab) and chemotherapy for previously-untreated metastatic pancreatic cancer patients is progressing well, targeting data readout in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000141057825001583/hcm-20250807xex99d1.htm)) |
| late 2025 | [ATLED (fanregratinib) topline data readout](https://sec-api.dev/pdufa/fanregratinib) | HCM |  | scheduled | "The first patient received the first dose in March 2023 and HUTCHMED expects to announce topline results from the study around the end of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000164825725000016/hcm-20250306xex99d1.htm)) |
| November 25, 2025 | [Hmpl-523(300mg po qd) primary completion](https://sec-api.dev/pdufa/hmpl-523) | HCM | Warm Antibody Autoimmune Hemolytic Anemia | completed | "NCT05535933 (HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-11-25 (ACTUAL); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05535933)) |
| Dec 2025 | [ENHERTU (trastuzumab deruxtecan) trial start](https://sec-api.dev/pdufa/trastuzumab-deruxtecan) | HCM | unresectable, advanced or metastatic HER2-expressing solid tumors | completed | "In December 2025, we initiated the global Phase I/IIa trial for HMPL-A251, to evaluate HMPL-A251 monotherapy in adult patients with unresectable, advanced or metastatic HER2-expressing solid tumors." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1648257/000110465926023822/hcm-20251231x20f.htm)) |
| 1H 2026 | [ATLED (fanregratinib) topline data readout](https://sec-api.dev/pdufa/fanregratinib) | HCM |  | scheduled | "We completed recruitment of the registrational cohort of a China Phase II trial in February 2025 and expect readout later in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000141057825001583/hcm-20250807xex99d1.htm)) |
| 1H 2026 | [ESLIM-02 NDA/BLA submission](https://sec-api.dev/pdufa/eslim-02) | HCM |  | scheduled | "A sNDA submission to the NMPA is planned in the first half of 2026 (NCT05535933)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000110465926023831/tm2525075d2_ex99-1.htm)) |
| Jan 2026 | [Sovleplenib topline data readout](https://sec-api.dev/pdufa/sovleplenib) | HCM |  | completed, met | "In the positive topline results announced in January 2026, the Phase III registration part met its primary endpoint of durable Hb response rate within weeks 5 to 24 of treatment." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1648257/000110465926023822/hcm-20251231x20f.htm)) |
| 1H 2026 | [ORPATHYS® (savolitinib) topline data readout](https://sec-api.dev/pdufa/savolitinib) | HCM |  | scheduled | "Our SAFFRON global Phase III study is ongoing and targets to complete patient enrollment in the second half of 2025 and readout data in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000141057825001583/hcm-20250807xex99d1.htm)) |
| Jan 2026 | [ESLIM-02 topline data readout](https://sec-api.dev/pdufa/eslim-02) | HCM |  | completed, positive | "We completed the ESLIM-02 China Phase III study for 2L wAIHA with positive topline results announced in January 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000110465926023831/tm2525075d2_ex99-1.htm)) |
| early 2026 | [ESLIM-02 topline data readout](https://sec-api.dev/pdufa/eslim-02) | HCM |  | scheduled | "The ESLIM-02 study in second-line warm autoimmune hemolytic anemia (wAIHA) has completed enrollment, with topline results expected in early 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000164825725000077/hcm-20251103xex99d1.htm)) |
| 1H 2026 | [Sovleplenib NDA/BLA submission](https://sec-api.dev/pdufa/sovleplenib) | HCM |  | scheduled | "HUTCHMED plans to submit the New Drug Application ("NDA") for sovleplenib for wAIHA to the China National Medical Products Administration (NMPA) in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000164825726000004/hcm-20260107xex99d1.htm)) |
| 1H 2026 | [HUTCHMED (China) Ltd topline data readout](https://sec-api.dev/companies/hcm/catalysts) | HCM |  | scheduled | "Topline results from the SAFFRON study are estimated to be reported in the first half of 2026, followed by submission of results for presentation at an appropriate medical congress." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000164825725000079/hcm-20251105xex99d1.htm)) |
| Jan 2026 | [HUTCHMED (China) Ltd topline data readout](https://sec-api.dev/companies/hcm/catalysts) | HCM |  | completed, met | "In the positive topline results announced in January 2026, the Phase III registration part met its primary endpoint of durable hemoglobin (Hb) response rate within weeks 5 to 24 of treatment." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1648257/000110465926023822/hcm-20251231x20f.htm)) |
| January 5, 2026 | [SULANDA® (surufatinib) trial start](https://sec-api.dev/pdufa/surufatinib) | HCM | metastatic pancreatic ductal adenocarcinoma | completed | "Hong Kong, Shanghai & Florham Park, NJ — Monday, January 5, 2026: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase III part of the Phase II/III trial to evaluate the efficacy of the combination of surufatinib, camrelizumab, nab-paclitaxel and gemcitabine as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma ("PDAC") in China." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000164825726000002/hcm-20260105xex99d1.htm)) |
| Feb 2026 | [Sovleplenib NDA/BLA submission](https://sec-api.dev/pdufa/sovleplenib) | HCM |  | completed | "NMPA accepted resubmitted NDA filing with priority review status and Breakthrough Designation for 2L ITP in February 2026, with additional data rolling in during the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000110465926088458/hcm-20260730xex99d1.htm)) |
| Mar 2026 | [TRUXIMA® (rituximab) trial start](https://sec-api.dev/pdufa/rituximab) | HCM | 2L relapsed/refractory DLBCL | completed | "Initiated China Phase III study in combination with R-GemOx (rituximab, gemcitabine and oxaliplatin) in patients with 2L relapsed/refractory DLBCL versus placebo in combination with R-GemOx in March 2026 (NCT07409428)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000110465926088458/hcm-20260730xex99d1.htm)) |
| March 23, 2026 | [HMPL-760 trial start](https://sec-api.dev/pdufa/hmpl-760) | HCM | relapsed/refractory diffuse large B-cell lymphoma | completed | "Hong Kong, Shanghai & Florham Park, NJ — Monday, March 23, 2026: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-760 in combination with R-GemOx (rituximab, gemcitabine and oxaliplatin) in patients with relapsed/refractory diffuse large B-cell lymphoma ("DLBCL") in China." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000164825726000021/hcm-20260323xex99d1.htm)) |
| May 23, 2026 | [Hmpl-760 planned dose 1 primary completion](https://sec-api.dev/pdufa/hmpl-760-planned) | HCM | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | completed | "NCT06601504 (Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-23 (ACTUAL); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06601504)) |
| 2H 2026 | [ORPATHYS® (savolitinib) topline data readout](https://sec-api.dev/pdufa/savolitinib) | HCM |  | scheduled | "Expecting topline results in H2 2026 for SAFFRON and SANOVO, following full enrollment in H2 2025:" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000110465926088458/hcm-20260730xex99d1.htm)) |
| August 28, 2026 | [Fruquintinib+sintilimab primary completion](https://sec-api.dev/pdufa/fruquintinib-sintilimab) | HCM | Advanced Renal Cell Carcinoma | completed | "NCT05522231 (Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-08-28 (ACTUAL); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05522231)) |
| Aug to Nov 2026 | [Fruquintinib+sintilimab topline data readout](https://sec-api.dev/pdufa/fruquintinib-sintilimab) | HCM | Advanced Renal Cell Carcinoma | scheduled | "NCT05522231 (Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-08-28 (ACTUAL); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05522231)) |
| late 2026 | [HUTCHMED (China) Ltd topline data readout](https://sec-api.dev/companies/hcm/catalysts) | HCM |  | scheduled | "Topline results from the SANOVO study are estimated to be reported in the second half of 2026, followed by submission of results for presentation at an appropriate medical congress." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000164825725000055/hcm-20250820xex99d1.htm)) |
| September 28, 2026 | [HUTCHMED (China) Ltd trial start](https://sec-api.dev/companies/hcm/catalysts) | HCM | unresectable, advanced or metastatic solid tumors | completed | "Hong Kong, Shanghai & Florham Park, NJ — Monday, September 28, 2026: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase Ia part of a global clinical trial of HMPL-A830 in patients with unresectable, advanced or metastatic solid tumors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000164825726000061/hcm-ex99d1.htm)) |
| September 29, 2026 | [ORPATHYS® (savolitinib) NDA/BLA submission](https://sec-api.dev/pdufa/savolitinib) | HCM | with locally advanced or metastatic non-small cell lung cancer | completed | "Hong Kong, Shanghai & Florham Park, NJ — Tuesday, September 29, 2026: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that AstraZeneca has submitted a New Drug Application ("NDA") to the US Food and Drug Administration ("FDA") for ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") whose tumors have MET overexpression or amplification, and who had disease progression on or after an epidermal growth factor receptor ("EGFR") tyrosine kinase inhibitor ("TKI") therapy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000164825726000064/hcm-ex99d1.htm)) |
| Apr to Jul 2028 | [HMPL-760 topline data readout](https://sec-api.dev/pdufa/hmpl-760) | HCM | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | scheduled | "NCT07409428 (A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-30 (ESTIMATED); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07409428)) |
| April 2028 | [HMPL-760 primary completion](https://sec-api.dev/pdufa/hmpl-760) | HCM | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | scheduled | "NCT07409428 (A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-30 (ESTIMATED); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07409428)) |
| May to Aug 2028 | [ORPATHYS® (savolitinib) topline data readout](https://sec-api.dev/pdufa/savolitinib) | HCM | Non-small Cell Lung Cancer | scheduled | "NCT05009836 (Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05-30 (ESTIMATED); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05009836)) |
| May to Aug 2028 | [Surufatinib combined with camrelizumab, nab-paclitaxel, and gemcitabine topline data readout](https://sec-api.dev/pdufa/surufatinib-combined-with-camrelizumab-nab-paclitaxel-and-gemcitabine) | HCM | Metastatic Pancreatic Cancer | scheduled | "NCT06361888 (A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06361888)) |
| May 2028 | [ORPATHYS® (savolitinib) primary completion](https://sec-api.dev/pdufa/savolitinib) | HCM | Non-small Cell Lung Cancer | scheduled | "NCT05009836 (Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05-30 (ESTIMATED); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05009836)) |
| May 2028 | [Surufatinib combined with camrelizumab, nab-paclitaxel, and gemcitabine primary completion](https://sec-api.dev/pdufa/surufatinib-combined-with-camrelizumab-nab-paclitaxel-and-gemcitabine) | HCM | Metastatic Pancreatic Cancer | scheduled | "NCT06361888 (A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06361888)) |
| Jun to Sep 2028 | [HMPL-453 topline data readout](https://sec-api.dev/pdufa/hmpl-453) | HCM | Advanced Intrahepatic Cholangiocarcinoma; Solid Tumor, Adult | scheduled | "NCT04353375 (HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04353375)) |
| June 2028 | [HMPL-453 primary completion](https://sec-api.dev/pdufa/hmpl-453) | HCM | Advanced Intrahepatic Cholangiocarcinoma; Solid Tumor, Adult | scheduled | "NCT04353375 (HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04353375)) |
| Dec 2028 to Mar 2029 | [Hmpl-306 regimen topline data readout](https://sec-api.dev/pdufa/hmpl-306-regimen) | HCM | Acute Myeloid Leukemia | scheduled | "NCT06387069 (A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-31 (ESTIMATED); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06387069)) |
| December 2028 | [Hmpl-306 regimen primary completion](https://sec-api.dev/pdufa/hmpl-306-regimen) | HCM | Acute Myeloid Leukemia | scheduled | "NCT06387069 (A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-31 (ESTIMATED); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06387069)) |
| Jan to Apr 2029 | [TYVYT® (sintilimab) topline data readout](https://sec-api.dev/pdufa/sintilimab) | HCM | Advanced Endometrial Cancer | scheduled | "NCT06584032 (Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-08 (ESTIMATED); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06584032)) |
| January 2029 | [TYVYT® (sintilimab) primary completion](https://sec-api.dev/pdufa/sintilimab) | HCM | Advanced Endometrial Cancer | scheduled | "NCT06584032 (Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-08 (ESTIMATED); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06584032)) |

## Drugs

- [AiRuiKa® (camrelizumab)](https://sec-api.dev/pdufa/camrelizumab): 
- [ESLIM-02](https://sec-api.dev/pdufa/eslim-02): 
- [ATLED (fanregratinib)](https://sec-api.dev/pdufa/fanregratinib): 
- [Fruquintinib+sintilimab](https://sec-api.dev/pdufa/fruquintinib-sintilimab): Advanced Renal Cell Carcinoma
- [Hmpl-306 regimen](https://sec-api.dev/pdufa/hmpl-306-regimen): Acute Myeloid Leukemia
- [HMPL-415](https://sec-api.dev/pdufa/hmpl-415): advanced malignant solid tumors
- [HMPL-453](https://sec-api.dev/pdufa/hmpl-453): Advanced Intrahepatic Cholangiocarcinoma
- [HMPL-506](https://sec-api.dev/pdufa/hmpl-506): hematological malignancies
- [Hmpl-523(300mg po qd)](https://sec-api.dev/pdufa/hmpl-523): Warm Antibody Autoimmune Hemolytic Anemia
- [HMPL-653](https://sec-api.dev/pdufa/hmpl-653): advanced or metastatic solid tumors and tgct
- [HMPL-760](https://sec-api.dev/pdufa/hmpl-760): r/r dlbcl, relapsed/refractory diffuse large b-cell lymphoma
- [Hmpl-760 planned dose 1](https://sec-api.dev/pdufa/hmpl-760-planned): Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- [Inmagene](https://sec-api.dev/pdufa/inmagene): 
- [ORPATHYS® (savolitinib)](https://sec-api.dev/pdufa/savolitinib): with locally advanced or metastatic non-small cell lung cancer, Non-small Cell Lung Cancer
- [TYVYT® (sintilimab)](https://sec-api.dev/pdufa/sintilimab): Advanced Endometrial Cancer
- [Sovleplenib](https://sec-api.dev/pdufa/sovleplenib): waiha in china, Primary Immune Thrombocytopenia (ITP)
- [SULANDA® (surufatinib)](https://sec-api.dev/pdufa/surufatinib): metastatic pancreatic ductal adenocarcinoma, pnets and non-pancreatic nets, pnets and epnets
- [Surufatinib combined with camrelizumab, nab-paclitaxel, and gemcitabine](https://sec-api.dev/pdufa/surufatinib-combined-with-camrelizumab-nab-paclitaxel-and-gemcitabine): Metastatic Pancreatic Cancer
- [TAZVERIK® (tazemetostat)](https://sec-api.dev/pdufa/tazemetostat): 
- [TQB3702](https://sec-api.dev/pdufa/tqb3702): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/hcm/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "HCM catalysts: HUTCHMED (China) Ltd PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/hcm/catalysts

```bibtex
@misc{secapidev_companies_hcm_catalysts_20261116,
  title        = {HCM catalysts: HUTCHMED (China) Ltd PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/hcm/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_hcm_catalysts_20261116","title":"HCM catalysts: HUTCHMED (China) Ltd PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/hcm/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
